Mouse Nerve Growth Factor for Injection

Pharmacological action: The results of in vivo tests on rats showed that this product can improve the limb motor dysfunction caused by toxic peripheral neuropathy caused by hexadione and acrylamide in rats, shorten the latency of nerve-muscle action potential, and increase the amplitude of nerve-muscle action potential. The results of histopathological examination showed that this product can reduce the incidence of myelin swelling of the animal tibial nerve and reduce the number of degenerated tibial nerve fibers. The above results suggest that this product may promote the recovery of damaged nerves. Toxicological study: The results of repeated toxicological tests showed that: (1) Wister rats were injected intramuscularly with 30mu;g/Kg, 60mu;g/Kg and 120mu;g/Kg of this product for 12 weeks. Only the animals in the 120mu;g/Kg dose group showed decreased appetite, delayed weight gain, and reduced activity after 28 days of administration. (2) The highest dose of this product was 17.8mu;g/Kg injected intramuscularly in mixed dogs. After 60 days of continuous administration, no obvious toxic reactions were observed in the animals. The results of general reproductive toxicity, teratogenic sensitive period and perinatal toxicity tests on Shanghai mice showed that when the dose was as high as 200mu;g/Kg, it had no obvious effect on the fertility of animals, embryonic organ formation and the development of F1 generation mice.

The active ingredient of this product is the purified nerve growth factor (mNGF) extracted from the mouse submandibular gland. The finished product contains 5% mannitol and 0.1% human blood protein as protective agents.

This product is white or off-white loose body or powder. After adding 2ml of normal saline or sterile water for injection, it will quickly dissolve into a colorless clear liquid.

Hexane toxic peripheral neuropathy.

This product is dissolved in 2 ml of injection water and injected intramuscularly. Once a day, one bottle (20g) each time. Four weeks is a course of treatment. Depending on the severity of the disease, multiple courses of continuous administration can be given as prescribed by the doctor.

1. No serious adverse reactions. Clinical trials found that some patients had transient elevations in transaminase. 2. Pain at the injection site or lower limb pain on the injection side is common after medication (the incidence rates are 85% and 29%, respectively), which generally does not require treatment. For some patients with more severe symptoms, oral analgesics can relieve them. 3. Other symptoms (such as dizziness, insomnia, etc.) are occasionally seen, and the incidence rate is not significantly different from that of the placebo group.

Do not use if you are allergic to this product.

Precautions for children: There is no data on the use of this drug in children in the study. Precautions for pregnancy and lactation: Because preclinical trials of this product showed that it has an inhibitory effect on the lactation of maternal rats, pregnant women, perinatal women and lactating women should use it with caution or follow the doctor's advice. Precautions for the elderly: There is no data on the use of this drug in patients over 65 years old in the study.

Not yet clear.

Store at 2-8℃ away from light. Valid for 30 months.

30μg (biological activity ≥15000AU)/bottle.

24 months

Staidson(Beijing) BioPharmaceuticals Co., Ltd.

• Founded in:

  2002-08-16

• Address:

  No. 36, Jinghai 2nd Road, Beijing Economic and Technological Development Zone, Beijing

• Tax NO.:

  911100007423131451

• Registered Funds:

  477.772555 million yuan

• Website:

  Log in to view

• Email:

  Log in to view